Cagrilintide + Semaglutide

Research Overview

This combination research vial provides researchers with a co-lyophilized preparation of two pharmacologically distinct receptor-targeting compounds: semaglutide (a long-acting acylated GLP-1 receptor agonist) and cagrilintide (a long-acting synthetic amylin analogue acting as a dual AMY1R/AMY3R co-agonist). The formulation is intended for preclinical research investigating whether concurrent GLP-1R agonism and amylin receptor co-agonism — operating through mechanistically distinct signalling pathways — produce additive or interactive metabolic signalling effects in experimental model systems. Two formulation variants are available to support different experimental concentration parameters. Supplied exclusively for laboratory and research use — not for human or animal consumption.

Research interest in the concurrent activation of GLP-1R and amylin receptor pathways stems from preclinical work indicating that these two receptor systems may regulate overlapping but distinct aspects of metabolic signalling — including hypothalamic energy balance circuits, gastric motility, and pancreatic signalling — through separate downstream mechanisms. Published investigational literature has examined whether combining a GLP-1 receptor agonist with an amylin receptor co-agonist produces metabolic signalling outcomes in preclinical models that exceed those observed with either receptor target in isolation, exploring the concept of additive multi-receptor pathway engagement in metabolic biology research. This combination research vial provides a standardised, single-vial format for researchers conducting such multi-receptor pathway studies. All outcomes referenced pertain to preclinical or investigational models and do not constitute evidence of clinical efficacy or safety in humans.